<DOC>
	<DOCNO>NCT00779103</DOCNO>
	<brief_summary>The purpose study follow collect additional medical developmental information child histrelin subcutaneous implant therapy discontinue .</brief_summary>
	<brief_title>Histrelin Subcutaneous Implant Children With Central Precocious Puberty</brief_title>
	<detailed_description>Thirty-two ( 32 ) patient receive histrelin subdermal implant anesthesia deem appropriate administering physician . Ten-twelve ( 10-12 ) sit enroll 2-3 patient per site . It anticipate half patient receive GnRH analog treatment half treatment na√Øve . All patient undergo selective PK sample post-implantation ass histrelin profile . At 12 month , provide patient continue meet safety efficacy parameter , original implant remove patient receive new implant . At 13 month , patient receive new implant evaluate study site administratively transfer initial extension study . At Month 24 ) , implant insert Month 12 remove . At time , patient complete initial extension study wish continue therapy histrelin implant eligible receive new ( ie , third ) implant enter additional 12-month extended access phase discretion investigator . At Month 36 , implant insert Month 24 Extended Access Phase remove . At time , patient complete Extended Access Phase wish continue therapy histrelin implant eligible receive new ( ie , fourth ) implant enter Long Term Extended Access Phase ( refer Implant Treatment Phase ) discretion investigator . The purpose phase provide patient opportunity continue receive new implant end 12-month period patient long require hormone suppression . Once implant therapy discontinue , patient eligible enter Long Term Follow Up Phase ( Post Implant Phase ) study .</detailed_description>
	<mesh_term>Puberty , Precocious</mesh_term>
	<criteria>Pretreated treatment naive patient gonadotropindependent precocious puberty Pretreatment pubertal type response LH stndard GnRH stimulation test initiation treatment Children le 2 year age enrollment Children whose chronological age great 8 year ( naive ) 10 year ( pretreated ) girl 9 year ( naive ) 11 year ( pretreated ) boys onset study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>puberty</keyword>
	<keyword>precocious puberty</keyword>
	<keyword>early puberty</keyword>
	<keyword>early onset puberty</keyword>
	<keyword>histrelin</keyword>
	<keyword>histrelin subcutaneous implant</keyword>
	<keyword>implant therapy</keyword>
</DOC>